Sydney West Translational Cancer Research Centre
Forgot Password?

NSW Early Phase Clinical Trial Alliance Annual Meeting

Mar
28
29

Location:

Garvan Institute, Sydney

Accelerating Collaboration. Recognising the potential for early phase clinical trials to drive advances in cancer care, we are arranging a national meeting to foster collaboration in the area.The speaker program includes both international and local thought leaders in drug development, biomarkers and radiopharmaceuticals.

DRAFT PROGRAMME 2019

755 Welcome A/Prof Anthony Joshua
800 Phase 1 Clinical Trials – Emerging Ethical Considerations – Prof Elizabeth Eisenhauer
900 The ups and downs of PI3K inhibitors in the clinic and lab – Are we ever going to get there? Professor Sarah Blagden
10-1030 Morning Tea
1030-1130 Ovarian cancer as a model for discoveries that will make their way to the clinic - Prof David Bowtell
1130-1230 Histomorphometrics and Radiomics in the clinic as biomarkers - Prof Anant Madabushi
1230-130 Lunch
130 Rapid Fire Showcase - Chair - Dr Amy Prawira
130-145 Rapid Fire Showcase AsiaPacific – Hong Kong (Loong)
145-2 Rapid Fire Showcase AsiaPacific – Singapore (Tan)
2-215 Rapid Fire Showcase AsiaPacific – New Zealand (Fong/ Deva)
215-230 Rapid Fire Showcase AsiaPacific – Sydney (Kuo)
230-245 Rapid Fire Showcase AsiaPacific- Hong Kong 2 (Chiu)
245-3 Rapid Fire Showcase AsiaPacific – Melbourne/ CTA (Tran)
3-315 Rapid Fire Showcase AsiaPacific – Taiwan (Lin)

315-345 Panel Discussion – Advancing Trials in the Asia-Pacific – How do we compete with USA/ Europe? Do we even care?
Discussants – Horvath, Fuller, Hausler + Rapid Fire people
345-420 Afternoon Tea
420-445 Radionucleotides in Phase 1 – Dr Peter Eu
445-515 Combinations with radionucleotides – Lessons and Future directions – A/Prof Shaneen Sandhu
515-530 Discussion

Day 2
Theme – Learning from Old things
830-915 Moving science to new targets - Prof Hansen He
915-10 What do we do for chemo protection in phase 1 designs? - ​Dr Catherine Han
10-1030 Morning Tea
1030-1115 Learning how to dose in phase 1 - Prof Steven Ackland
1115-12 Impact of Genomics on Drug Development and Radiation - Prof Felix Feng
12-1 Lunch
1-130 Pipeline Presentation - Bayer
130-2 Pipeline Presentation - Pfizer
2-230 Pipeline Presentation - Sanofi
230-3 Pipeline Presentation - BMS
3-330 Pipeline Presentation- Merck Serono
330-4 Pipeline Presentation- Novartis
4-430 Pipeline Presentation- GSK
430-5 Pipeline Presentation- Abbvie